Company Overview and News

1
Bayer AG: A Good Opportunity To Buy The Dips

2018-10-11 seekingalpha
Share prices have been thrashed during the past 12 months and it is time for a rebound.
BFFAF NVS BFA BASFY

 
Bayer Cutting More than 200 Jobs in San Francisco Bay Area

2018-10-04 biospace
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
BFFAF BFA BASFY

 
Wintershall and DEA to Merge

2018-09-28 rigzone
Closing of the transaction is expected in the first half of 2019, subject to approvals of merger control and foreign investment authorities as well as mining authorities and the German Federal Network Agency.
BFFAF BFA BASFY

2
Winners and losers from Donald Trump's tariffs

2018-09-19 nzherald.co.nz
President Donald Trump set the world's two largest economies on course for an all-out trade war, unleashing a list of US$200 billion ($303.6b) of Chinese products set for tariffs just as the critical holiday shopping season begins.
SMSOF TGT FIT SMSEY 1910 BFFAF SHOO BFA BASFY

3
Winners and losers from Trump tariffs: Apple, bikes, Americans

2018-09-18 theedgemarkets
SYDNEY (Sept 18): President Donald Trump set the world’s two largest economies on course for an all-out trade war, unleashing a list of US$200 billion of Chinese products set for tariffs just as the critical holiday shopping season begins.
SMSOF TGT FIT SMSEY 1910 AAPL BFFAF SHOO BFA BASFY

1
US Warns Russia It May Sanction New Gas Pipeline to Germany

2018-09-13 rigzone
(Bloomberg) -- The U.S. warned Russia that it may follow through on sanction threats over the construction of a major natural gas pipeline to Germany.
RDS.B RDS.A UNPPY OMVKY RDSB RDSA UNPRF OMVJF ENGI OMVZY RYDBF BFFAF BFA BASFY RYDAF

 
Bayer delays in Monsanto buy hurt earnings forecast

2018-09-06 thestar.com.my
Legal troubles: The Bayer AG logo sits on a sign beside a field of crops at a farm in Abbenes, Netherlands. While acquiring Monsanto made Bayer the biggest seed and agricultural chemicals maker in the world, the purchase has been dogged by a series of regulatory challenges and legal pitfalls. — Bloomberg
BFFAF BFA BASFY

1
‘No regrets’ for $63 billion Monsanto purchase, says Bayer CEO Baumann

2018-09-05 livemint
Berlin/New York: Bayer AG’s $63 billion Monsanto purchase has suffered regulatory delays, mounting legal claims and now will yield lower earnings for the year than earlier forecast. Still, the company’s CEO says he has “no regrets.”
MON BFFAF BFA BASFY

7
EPA should revoke Monsanto weed killer approval, groups tell U.S. court

2018-08-29 reuters
(Reuters) - Environmental groups argued in federal appeals court on Wednesday the U.S. Environmental Protection Agency failed to analyze the risks Bayer AG (BAYGn.DE) Monsanto’s dicamba-based weed killer posed to nearby crops before approving it in 2016.
BFFAF BFA BASFY DWDP

8
Deals of the day-Mergers and acquisitions

2018-08-28 reuters - 1
Aug 28 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Tuesday:
VMW APO HSB BFFAF HSBC HBCYF TRBAB TRBNW 98LQ HCS 0005 AHL HLPD HSEA HSEB BASFY BFA FPM SBGI BRKS TRCO

1
Crystal Crop acquires 4 brands from FMC, to widen portfolio

2018-08-20 livemint
Mumbai: Crystal Crop Protection Ltd, a specialty chemicals company focused on crop protection, on Monday said it has acquired four brands from American chemicals major FMC Corp., marking the company’s third inorganic growth initiative this calendar year.
FTI.WI FMC BFFAF BFA BASFY

8
Exclusive: US seed sellers push for limits on Monsanto, BASF weed killer

2018-08-16 channelnewsasia
America's two biggest independent seed sellers, Beck's Hybrids and Stine Seed, told Reuters they are pushing U.S. environmental regulators to bar farmers from spraying dicamba weed killer during upcoming summers in a potential blow to Bayer AG's Monsanto Co.
MON BFFAF BFA BASFY DWDP

8
Exclusive: U.S. seed sellers push for limits on Monsanto, BASF weed killer

2018-08-16 reuters
CHICAGO (Reuters) - America’s two biggest independent seed sellers, Beck’s Hybrids and Stine Seed, told Reuters they are pushing U.S. environmental regulators to bar farmers from spraying dicamba weed killer during upcoming summers in a potential blow to Bayer AG’s Monsanto Co.
MON BFFAF BFA BASFY DWDP

8
Bayer shares drop after Monsanto loses Roundup cancer trial

2018-08-13 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
MON BFFAF BFA BASFY DWDP

1
Trump says U.S. will compete with Russia for European gas market

2018-07-16 worldoil
MOSCOW (Bloomberg) -- U.S. President Donald Trump eased his tone about a Russian natural gas pipeline to Germany after a one-on-one meeting with President Vladimir Putin, shifting from the harsh criticism he’d levied in Europe last week.
RDS.B RDS.A UNPPY OMVKY RDSB RDSA UNPRF OMVJF ENGI OMVZY RYDBF BFFAF BFA BASFY RYDAF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...